Saturday 17 October 2026 Export PRQR’s income statement to Excel — free account

ProQR Therapeutics N.V.

ProQR Therapeutics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $18.0 million, down 12.0% from fiscal 2024. In the quarter to June 2026, revenue grew 135.0%, EPS grew 28.6%, free cash flow fell 1.06% and total debt rose 8.71%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.31 0.14 −9.66%

Follow PRQR

Alert me

Market cap: $204.6M
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: 1/9
Altman Z: −4.43
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.34

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	4	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 10.65%

Capital & Financial Ratios $m

Market Cap 204.63

Revenue 21.47

Net Income (48.17)

Free Cash Flow (57.39)

Net Debt (130.35)

Current Ratio 3.49

Debt/Equity 0.06

P/E ratio 0.00

Fwd P/E (2.51)

P/S ratio 6.71

P/B ratio 1.56

Past 5Y EPS Growth —

This Y EPS Growth (6.47%)

Next Y EPS Growth (16.17%)

Next Y revenue growth 13.80%

Next 5Y EPS Growth 10.96%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.40%

10-year low 10-year high

P/B against its own 10 years 14.63%

10-year low 10-year high

EV/Sales against its own 10 years 3.21%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	129	162	105	136
Receivables	—	—	8	5
Inventory	—	—	—	—
Other	1	1	1	1
	131	166	113	141

	2023	2024	2025	Q'26
Payables	2	0	0	—
ST’ Debt	—	5	6	6
Other	11	12	9	12
	37	42	37	41

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	61.74%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(5.63%)	(2.86%)	(6.62%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	10	—	—	—
’25	5	4	3	6	18
’24	5	7	4	5	20
’23	1	1	1	4	7
’22	1	1	1	1	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(14)	—	—	—
’25	(17)	(14)	(15)	(14)	(60)
’24	(16)	(7)	(7)	(10)	(39)
’23	48	(11)	(8)	(6)	23
’22	(23)	(15)	(13)	(21)	(72)
’21	(14)	(12)	(9)	4	(31)
’20	(17)	(12)	(13)	(12)	(54)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(15)	—	—	—
’25	(17)	(14)	(15)	(14)	(61)
’24	(17)	(7)	(7)	(10)	(41)
’23	48	(11)	(9)	(7)	30
’22	(23)	(15)	(14)	(21)	(73)
’21	(14)	(12)	(9)	4	(31)
’20	(17)	(12)	(14)	(13)	(55)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.15)	(0.10)	—	—	—
’25	(0.11)	(0.14)	(0.12)	(0.09)	(0.45)
’24	(0.10)	(0.03)	(0.11)	(0.10)	(0.35)
’23	(0.12)	(0.11)	(0.08)	(0.08)	(0.38)
’22	(0.22)	(0.22)	(0.34)	(0.16)	(0.96)
’21	(0.30)	(0.29)	(0.26)	(0.30)	(1.14)
’20	(0.35)	(0.09)	(0.36)	(0.31)	(1.06)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.48	2.75	2.80	5.49	3.40	4.00	0.53	1.11	1.61	1.07	Analyst estimates 2026–2028 Powerpack
	High	8.96	6.90	24.00	18.94	10.09	9.46	8.60	3.85	4.62	3.10
People
People	Employees	133	130	118	154	150	182	130	156	166	187
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.01	0.03	0.05	0.12	0.10
Income, $m
Income, $m	Revenue	—	—	—	—	—	2	4	7	20	18
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00
	EBT	(43)	(49)	(44)	(63)	(53)	(73)	(68)	(30)	(30)	(48)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(4,546.80)	(1,605.02)	(426.97)	(147.90)	(265.09)
	Net income	(43)	(49)	(44)	(64)	(53)	(73)	(68)	(30)	(30)	(48)
	Depreciation	1	1	1	2	3	3	3	3	3	3
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.03	0.06	0.09	0.24	0.17
	Earnings	(1.85)	(1.94)	(1.29)	(1.55)	(1.06)	(1.14)	(0.96)	(0.38)	(0.35)	(0.45)
	Cash flow	(1.62)	(1.56)	(0.99)	(1.20)	(1.07)	(0.48)	(1.01)	0.29	(0.46)	(0.57)
	Capex	(0.12)	(0.01)	(0.01)	(0.02)	(0.02)	(0.01)	(0.01)	0.09	(0.02)	(0.01)
	Free cash flow	(1.74)	(1.56)	(1.00)	(1.22)	(1.09)	(0.49)	(1.02)	0.38	(0.48)	(0.58)
	Book value	2.52	1.75	3.21	2.56	1.29	2.09	0.96	0.55	1.11	0.53
	Shares, m	23	25	34	41	50	64	72	81	86	105
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	0.00	57.44	23.90	11.15	11.82
	P/B	—	—	—	—	—	3.84	3.56	3.76	2.38	3.81
	EV/Sales	—	—	—	—	—	0.00	35.64	6.66	3.72	6.58
	EV/FCF	—	—	—	—	—	(11.01)	(2.08)	2.15	(1.86)	(1.94)
Cash, $m
Cash, $m	Operating cash flow	(38)	(40)	(34)	(49)	(54)	(31)	(72)	23	(39)	(60)
	Capex	(3)	0	0	(1)	(1)	(1)	(1)	7	(2)	(1)
	Free cash flow	(41)	(40)	(34)	(50)	(55)	(31)	(73)	30	(41)	(61)
Balance, $m
Balance, $m	Working capital	61	48	118	116	80	194	140	94	124	77
	Total debt	6	8	11	15	20	52	7	5	5	6
	Net debt	(59)	(46)	(114)	(111)	(67)	(170)	(93)	(124)	(157)	(99)
	Shareholders’ equity	59	44	109	105	65	134	69	45	96	56
Returns, %
Returns, %	ROA	(47.11)	(74.42)	(45.82)	(48.55)	(43.52)	(40.42)	(32.02)	(18.46)	(18.15)	(30.86)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(54.60)	(95.54)	(56.62)	(59.24)	(62.69)	(73.43)	(67.73)	(53.67)	(42.73)	(62.93)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IFRX InflaRx N.V.	$212.2M	— (loss-making)	— (loss-making)	−128.93% (below 0%: shrinking)	n/m	+69.33% (above 0%: growing)	14,029.95%	0.00%	Compare
ZNTL Zentalis Pharmaceuticals, Inc.	$212.1M	— (loss-making)	— (loss-making)	—	n/m	−9.06% (below 0%: shrinking)	100.00%	0.00%	Compare
LRMR Larimar Therapeutics, Inc.	$206.7M	— (loss-making)	—	—	n/m	−127.63% (below 0%: shrinking)	0.00%	0.00%	Compare
PRQR ProQR Therapeutics N.V.	$204.6M	— (loss-making)	— (loss-making)	+135.03% (above 0%: growing)	n/m	−1.06% (below 0%: shrinking)	100.00%	(100.72%)
NAGE Niagen Bioscience, Inc.	$204.2M	12.5×	15.0×	−4.28% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+140.63% (above 0%: growing)	64.84%	2.35%	Compare
LYEL Lyell Immunopharma, Inc.	$200.7M	— (loss-making)	— (loss-making)	−50.00% (below 0%: shrinking)	n/m	+1.31% (above 0%: growing)	100.00%	(1,183,425.00%)	Compare
RNAC Cartesian Therapeutics, Inc.	$199.1M	— (loss-making)	— (loss-making)	−92.91% (below 0%: shrinking)	−7.84% (below 0%: shrinking)	−6.15% (below 0%: shrinking)	100.00%	0.00%	Compare
IVVD Invivyd, Inc.	$197.1M	— (loss-making)	— (loss-making)	+21.20% (above 0%: growing)	n/m	−226.89% (below 0%: shrinking)	91.09%	(320.76%)	Compare
CGEN Compugen Ltd.	$197.0M	5.2×	— (loss-making)	+107.00% (above 0%: growing)	n/m	−155.42% (below 0%: shrinking)	(3.54%)	(339.62%)	Compare
Median of peers	$202.4M	—	—	−27.14%	—	−7.60%	95.55%	0.00%

All 614 Biotechnology stocks →

ProQR Therapeutics N.V. (PRQR) key facts

Concern: ProQR Therapeutics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $18.0 million, down 12.0% from fiscal 2024.
Concern: ProQR Therapeutics N.V. reported a net loss of $47.7 million, or a loss of $0.45 per share, for fiscal 2025.
ProQR Therapeutics N.V. (PRQR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PRQR traded at $1.31, a market capitalization of $204.6 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 6.7× sales.
Return on equity was −62.9% and debt-to-equity 0.06.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −4.43 (distress zone) for fiscal 2025.